These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 9165547)

  • 1. Pharmacometric analysis of the effect of furosemide on suramin pharmacokinetics.
    Piscitelli SC; Forrest A; Lush RM; Ryan N; Whitfield LR; Figg WD
    Pharmacotherapy; 1997; 17(3):431-7. PubMed ID: 9165547
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer.
    Jodrell DI; Reyno LM; Sridhara R; Eisenberger MA; Tkaczuk KH; Zuhowski EG; Sinibaldi VJ; Novak MJ; Egorin MJ
    J Clin Oncol; 1994 Jan; 12(1):166-75. PubMed ID: 8270974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
    Ahles TA; Herndon JE; Small EJ; Vogelzang NJ; Kornblith AB; Ratain MJ; Stadler W; Palchak D; Marshall ME; Wilding G; Petrylak D; Holland JC;
    Cancer; 2004 Nov; 101(10):2202-8. PubMed ID: 15484217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
    Vogelzang NJ; Karrison T; Stadler WM; Garcia J; Cohn H; Kugler J; Troeger T; Giannone L; Arrieta R; Ratain MJ; Vokes EE
    Cancer; 2004 Jan; 100(1):65-71. PubMed ID: 14692025
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of adaptive control with feedback to individualize suramin dosing.
    Scher HI; Jodrell DI; Iversen JM; Curley T; Tong W; Egorin MJ; Forrest A
    Cancer Res; 1992 Jan; 52(1):64-70. PubMed ID: 1727387
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effectiveness of furosemide in patients on peritoneal dialysis.
    Flinn A; Ledger S; Blake P
    CANNT J; 2006; 16(3):40-4. PubMed ID: 17061696
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.
    Villalona-Calero MA; Wientjes MG; Otterson GA; Kanter S; Young D; Murgo AJ; Fischer B; DeHoff C; Chen D; Yeh TK; Song S; Grever M; Au JL
    Clin Cancer Res; 2003 Aug; 9(9):3303-11. PubMed ID: 12960116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of suramin plus aminoglutethimide in two cohorts of patients with androgen-independent prostate cancer: simultaneous antiandrogen withdrawal and prior antiandrogen withdrawal.
    Dawson N; Figg WD; Brawley OW; Bergan R; Cooper MR; Senderowicz A; Headlee D; Steinberg SM; Sutherland M; Patronas N; Sausville E; Linehan WM; Reed E; Sartor O
    Clin Cancer Res; 1998 Jan; 4(1):37-44. PubMed ID: 9516950
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor and basic fibroblast growth factor urine levels as predictors of outcome in hormone-refractory prostate cancer patients: a cancer and leukemia group B study.
    Bok RA; Halabi S; Fei DT; Rodriquez CR; Hayes DF; Vogelzang NJ; Kantoff P; Shuman MA; Small EJ
    Cancer Res; 2001 Mar; 61(6):2533-6. PubMed ID: 11289126
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suramin, an active drug for prostate cancer: interim observations in a phase I trial.
    Eisenberger MA; Reyno LM; Jodrell DI; Sinibaldi VJ; Tkaczuk KH; Sridhara R; Zuhowski EG; Lowitt MH; Jacobs SC; Egorin MJ
    J Natl Cancer Inst; 1993 Apr; 85(8):611-21. PubMed ID: 8468719
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of high-dose furosemide and small-volume hypertonic saline solution infusion in comparison with a high dose of furosemide as bolus in refractory congestive heart failure: long-term effects.
    Licata G; Di Pasquale P; Parrinello G; Cardinale A; Scandurra A; Follone G; Argano C; Tuttolomondo A; Paterna S
    Am Heart J; 2003 Mar; 145(3):459-66. PubMed ID: 12660669
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
    Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
    Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of furosemide regimens in neonates treated with extracorporeal membrane oxygenation.
    van der Vorst MM; Wildschut E; Houmes RJ; Gischler SJ; Kist-van Holthe JE; Burggraaf J; van der Heijden AJ; Tibboel D
    Crit Care; 2006; 10(6):R168. PubMed ID: 17140428
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I/II study of continuous infusion suramin in patients with hormone-refractory prostate cancer: toxicity and response.
    Bowden CJ; Figg WD; Dawson NA; Sartor O; Bitton RJ; Weinberger MS; Headlee D; Reed E; Myers CE; Cooper MR
    Cancer Chemother Pharmacol; 1996; 39(1-2):1-8. PubMed ID: 8995493
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population pharmacokinetics of the photodynamic therapy agent 2-[1-hexyloxyethyl]-2-devinyl pyropheophorbide-a in cancer patients.
    Bellnier DA; Greco WR; Loewen GM; Nava H; Oseroff AR; Pandey RK; Tsuchida T; Dougherty TJ
    Cancer Res; 2003 Apr; 63(8):1806-13. PubMed ID: 12702566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of the MDR inhibitor Incel (biricodar, VX-710) in combination with mitoxantrone and prednisone in hormone-refractory prostate cancer.
    Rago RP; Einstein A; Lush R; Beer TM; Ko YJ; Henner WD; Bubley G; Merica EA; Garg V; Ette E; Harding MW; Dalton WS
    Cancer Chemother Pharmacol; 2003 Apr; 51(4):297-305. PubMed ID: 12721757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nontoxic doses of suramin enhance activity of doxorubicin in prostate tumors.
    Zhang Y; Song S; Yang F; Au JL; Wientjes MG
    J Pharmacol Exp Ther; 2001 Nov; 299(2):426-33. PubMed ID: 11602651
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of biomarkers of survival response in hormone-refractory prostate cancer patients treated with suramin.
    Sridhara R; Eisenberger MA; Sinibaldi VJ; Reyno LM; Egorin MJ
    Cancer Epidemiol Biomarkers Prev; 1998 Jul; 7(7):631-4. PubMed ID: 9681533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of suramin in treatment of prostatic carcinoma refractory to conventional hormonal manipulation.
    LaRocca RV; Cooper MR; Uhrich M; Danesi R; Walther MM; Linehan WM; Myers CE
    Urol Clin North Am; 1991 Feb; 18(1):123-9. PubMed ID: 1992566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Furosemide does not improve renal recovery after hemofiltration for acute renal failure in critically ill patients: a double blind randomized controlled trial.
    van der Voort PH; Boerma EC; Koopmans M; Zandberg M; de Ruiter J; Gerritsen RT; Egbers PH; Kingma WP; Kuiper MA
    Crit Care Med; 2009 Feb; 37(2):533-8. PubMed ID: 19114909
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.